July 1 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX :
* FDA GRANTS BREAKTHROUGH DESIGNATION FOR TLX250-CDX PRODUCT
* US FDA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR RENAL CANCER IMAGING PRODUCT
July 1 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX :
* FDA GRANTS BREAKTHROUGH DESIGNATION FOR TLX250-CDX PRODUCT
* US FDA GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR RENAL CANCER IMAGING PRODUCT